HuR Targeted Nanotherapy for Lung Cancer

HuR 靶向纳米疗法治疗肺癌

基本信息

项目摘要

DESCRIPTION (provided by applicant): Lung cancer remains a major health problem in the world. Despite advances in treatment strategies the overall 5-year survival rate is only 14%. Therefore, novel therapies are needed. One attractive therapeutic approach is to identify a molecular target that is overexpressed in lung cancer and which regulates the expression of several cellular proteins that support cancer growth and metastasis. By inhibiting such a molecular target a global inhibitory effect on the expression of several proteins in a cancer cell will be produced resulting in anticancer activity. HuR, a member of the embryonic lethal abnormal vision (ELAV) protein family, is one such protein that controls the translation of numerous proteins and overexpressed in human cancers. HuR is a nucleo-cytoplasmic shuttling protein that specifically binds to mRNA that has AU rich (ARE) sites at the 3'end and transports the mRNA to the cytoplasm for protein translation. In addition to mRNA transportation, HuR plays a role in mRNA stabilization and protein translation. Studies have shown mRNA's of several growth factors, cell-cycle regulators, and transcription- regulating proteins have AREs and are bound and regulated by HuR. Additionally, HuR expression has been demonstrated to be a poor prognostic marker in patients diagnosed with cancer of the ovary, breast and colon. Although studies investigating HuR in cancer exist, the role of HuR in lung cancer, especially in non-small cell lung cancer (NSCLC), has not been investigated. In addition, very few therapeutic studies targeting HuR for cancer therapy have been investigated. On the basis of the existing literature and our own preliminary data demonstrating HuR overexpression in human lung cancer tissues we hypothesize that HuR is a novel druggable target for cancer therapy and its inhibition will downregulate multiple oncoproteins that play a role in tumor progression resulting in enhanced tumor killing. Additionally, combining HuR-targeted therapy with small molecule inhibitors will produce enhanced anticancer activity. To test our hypothesis we have identified the following specific aims: Aim 1: Cellular and molecular characterization of HuRSiRNA-Tf-nanoparticles (HuR-TfNPs) treatment on human lung tumor and normal cell lines in vitro. Aim 2: Evaluate the efficacy of HuR-TfNPs on lung metastasis in a tumor xenograft mouse model. Aim 3: Determine the efficacy of HuR-TfNPs treatment in combination with small molecule inhibitors in vitro and in vivo. The outcome of our studies will result in advanced preclinical testing and translation to the clinic.
描述(由申请人提供):肺癌仍然是世界上一个主要的健康问题。尽管治疗策略有所进步,但总体5年生存率仅为14%。因此,需要新的治疗方法。一种有吸引力的治疗方法是确定在肺癌中过度表达的分子靶标,并调节支持癌症生长和转移的几种细胞蛋白的表达。通过抑制这样一个分子靶点,将对癌细胞中几种蛋白质的表达产生全局抑制作用,从而产生抗癌活性。HuR是胚胎致死性异常视力(ELAV)蛋白家族的一员,是一种控制许多蛋白质翻译并在人类癌症中过度表达的蛋白质。HuR是一种核细胞质穿梭蛋白,它特异性地与3'端富含AU (ARE)位点的mRNA结合,并将mRNA转运到细胞质中进行蛋白质翻译。除了mRNA运输外,HuR还在mRNA稳定和蛋白质翻译中发挥作用。研究表明,几种生长因子、细胞周期调节因子和转录调节蛋白的mRNA具有AREs,并受HuR的结合和调节。此外,HuR表达已被证明是卵巢癌、乳腺癌和结肠癌患者预后不良的标志。虽然有研究探讨了HuR在癌症中的作用,但HuR在肺癌,特别是非小细胞肺癌(NSCLC)中的作用尚未得到研究。此外,针对HuR的癌症治疗研究很少。根据现有文献和我们自己在人肺癌组织中显示HuR过表达的初步数据,我们假设HuR是一种新的癌症治疗药物靶点,其抑制会下调多种在肿瘤进展中起作用的癌蛋白,从而增强肿瘤杀伤。此外,将hr靶向治疗与小分子抑制剂结合将产生增强的抗癌活性。为了验证我们的假设,我们确定了以下具体目标:目标1:体外研究hursirna - tf纳米颗粒(huri - tfnps)对人肺肿瘤和正常细胞系治疗的细胞和分子特性。目的2:评价HuR-TfNPs对肿瘤移植小鼠肺转移的影响。目的3:确定hr - tfnps与小分子抑制剂联合治疗的体内外疗效。我们的研究结果将导致先进的临床前测试和转化为临床。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rajagopal Ramesh其他文献

Rajagopal Ramesh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rajagopal Ramesh', 18)}}的其他基金

Engineered Nanoformulation for Immune-modulation in Cancer
用于癌症免疫调节的工程纳米制剂
  • 批准号:
    10719487
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
Exosomes as carriers of cancer therapeutics
外泌体作为癌症治疗的载体
  • 批准号:
    10312645
  • 财政年份:
    2021
  • 资助金额:
    $ 38.02万
  • 项目类别:
ShEEP Request for CytoViva 3D Darkfield Hyperspectral Microscope
ShEEP 请求 CytoViva 3D 暗场高光谱显微镜
  • 批准号:
    9906462
  • 财政年份:
    2019
  • 资助金额:
    $ 38.02万
  • 项目类别:
An improved IL-24 gene-based therapeutic for cancer
改进的基于 IL-24 基因的癌症疗法
  • 批准号:
    10326352
  • 财政年份:
    2019
  • 资助金额:
    $ 38.02万
  • 项目类别:
An improved IL-24 gene-based therapeutic for cancer
改进的基于 IL-24 基因的癌症疗法
  • 批准号:
    10544003
  • 财政年份:
    2019
  • 资助金额:
    $ 38.02万
  • 项目类别:
Cancer Research Training and Education Coordination
癌症研究培训和教育协调
  • 批准号:
    10627028
  • 财政年份:
    2018
  • 资助金额:
    $ 38.02万
  • 项目类别:
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance
铂类药物对蛋白酶体和 SQSTM1_P62 复合物的分子影响_耐药范式转变
  • 批准号:
    10051382
  • 财政年份:
    2017
  • 资助金额:
    $ 38.02万
  • 项目类别:
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance
铂类药物对蛋白酶体和 SQSTM1_P62 复合物的分子影响_耐药范式转变
  • 批准号:
    9478535
  • 财政年份:
    2017
  • 资助金额:
    $ 38.02万
  • 项目类别:
HuR Targeted Nanotherapy for Lung Cancer
HuR 靶向纳米疗法治疗肺癌
  • 批准号:
    8601528
  • 财政年份:
    2013
  • 资助金额:
    $ 38.02万
  • 项目类别:
HuR Targeted Nanotherapy for Lung Cancer
HuR 靶向纳米疗法治疗肺癌
  • 批准号:
    8440451
  • 财政年份:
    2013
  • 资助金额:
    $ 38.02万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 38.02万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了